Breast cancers are primarily divided into four molecular subtypes based on their pathological characteristics: Hormone receptor positive (Luminal A and Luminal B), HER2 positive, and Triple Negative. Among these subtypes, hormone (endocrine) therapies are administered only to patients with hormone receptor positive breast cancer.